Sponsor pipeline

AbbVie clinical trial pipeline

Get alerts when AbbVie's trials change

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-23

What changed in the last 30 days

47 trials changed in the last 30 days: 2 stopped, 13 with notable changes, 32 with minor changes only.

Stopped

Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies · Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Trial terminated

Also in this update: Primary completion date changed from estimate of Feb 2027 to Sep 18, 2026

AbbViePhase 1 NCT06487559 Registry history of NCT06487559 on ClinicalTrials.gov (opens the registry)

Oct 21, 2026
Stopped

LIVEN · Change in Disease State · Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada

Trial terminated

Also in this update: Primary completion date changed from estimate of Mar 2027 to Aug 31, 2026

AbbVieNot specified NCT05424562 Registry history of NCT05424562 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Notable

Change in Disease Activity and Adverse Events (AE)s · Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Primary endpoint(s) modified

Also in this update: Interventions modified; Study completion pushed from Dec 2035 to Mar 2036

AbbViePhase 1/2 NCT06892522 Registry history of NCT06892522 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

Different Targeted Therapies · Rheumatoid Arthritis

Primary endpoint(s) modified

Also in this update: Interventions modified; Trial arms changed: 12 → 6

AbbViePhase 2 NCT06972446 Registry history of NCT06972446 on ClinicalTrials.gov (opens the registry)

Oct 8, 2026
Notable

Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs · Ovarian Cancer

Primary endpoint(s) modified

Also in this update: Enrollment increased: 219 → 285 participants; Trial sites expanded: 17 → 22 locations; and 1 more change in the last 30 days

AbbViePhase 1 NCT07278336 Registry history of NCT07278336 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026
Notable

U-EMPOWER · Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib · Moderately to Severely Active Crohn's Disease

Primary completion pushed from Jun 2027 to Jan 2031

Also in this update: Enrollment closed, study ongoing; Study completion moved earlier from Dec 2034 to Jan 2031

AbbViePhase 3 NCT06332534 Registry history of NCT06332534 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Notable

How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

Primary and study completion pushed from Aug 2027 to May 2028

Also in this update: Enrollment increased: 121 → 142 participants; Trial sites reduced: 23 → 20 locations

AbbViePhase 1 NCT07232004 Registry history of NCT07232004 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Notable

Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment · Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Primary completion pushed from Dec 2031 to Nov 2036

Also in this update: Trial sites expanded: 53 → 65 locations

AbbViePhase 2/3 NCT07005102 Registry history of NCT07005102 on ClinicalTrials.gov (opens the registry)

Oct 5, 2026
Notable

Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

Primary and study completion pushed from Sep 2027 to Jun 2028

AbbVieNot specified NCT06916507 Registry history of NCT06916507 on ClinicalTrials.gov (opens the registry)

Oct 2, 2026
Notable

Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan · c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Phase changed: Phase 3 → Phase 2

AbbViePhase 2 NCT06614192 Registry history of NCT06614192 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026
Notable

Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

Recruitment opened

AbbViePhase 3 NCT07756645 Registry history of NCT07756645 on ClinicalTrials.gov (opens the registry)

Oct 20, 2026
Notable

Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body · Advanced Solid Tumors

Recruitment opened

Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Sep 1, 2026 to Sep 14, 2026

AbbViePhase 1 NCT07807956 Registry history of NCT07807956 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Notable

AURA · Participant Satisfaction After Jawline and Neck Treatment

Recruitment opened

Also in this update: Start date changed from estimate of Sep 4, 2026 to Sep 9, 2026

AbbViePhase 4 NCT07794891 Registry history of NCT07794891 on ClinicalTrials.gov (opens the registry)

Oct 8, 2026
Notable

Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruitment opened

Also in this update: Trial sites expanded: 0 → 3 locations

AbbViePhase 2 NCT07744126 Registry history of NCT07744126 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Notable

Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Primary completion moved earlier from Apr 2031 to Mar 2030

AbbViePhase 3 NCT07821684 Registry history of NCT07821684 on ClinicalTrials.gov (opens the registry)

Oct 5, 2026

Show 32 trials with minor changes only

Minor

LIVIGNO-4 · Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy · Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Enrollment closed, study ongoing

Also in this update: Final enrollment: 167 participants (planned 840)

AbbViePhase 2/3 NCT06236438 Registry history of NCT06236438 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Start Up · Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Enrollment closed, study ongoing

Also in this update: Primary and study completion moved earlier from Jul 2030 to Nov 2029

AbbViePhase 3 NCT06461897 Registry history of NCT06461897 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Switch-Up · Upadacitinib · Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Enrollment closed, study ongoing

Also in this update: Primary completion pushed from Aug 2026 to Nov 2026; Study completion pushed from Mar 2027 to May 2027

AbbViePhase 3 NCT06389136 Registry history of NCT06389136 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Oral Armour Thyroid Compared to Synthetic T4 · Primary Hypothyroidism in Adult Participants

Enrollment closed, study ongoing

AbbViePhase 2/3 NCT06345339 Registry history of NCT06345339 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

Trial completed

Also in this update: Enrollment reduced: 48 → 36 participants; Study completion date changed from estimate of Nov 2026 to Sep 18, 2026; and 1 more change in the last 30 days

AbbViePhase 1 NCT07222709 Registry history of NCT07222709 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

ADVISE MCOS · Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) · Atopic Dermatitis

Trial completed

AbbVieNot specified NCT05081557 Registry history of NCT05081557 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) · Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Primary completion pushed from Sep 2040 to Mar 2041

Also in this update: Study completion pushed from May 2041 to Jan 2042

AbbViePhase 2/3 NCT07095452 Registry history of NCT07095452 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants

Enrollment closed, study ongoing

AbbViePhase 1 NCT07680686 Registry history of NCT07680686 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

Trial completed

AbbViePhase 1 NCT06953934 Registry history of NCT06953934 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants

Trial completed

AbbViePhase 3 NCT07032597 Registry history of NCT07032597 on ClinicalTrials.gov (opens the registry)

Oct 5, 2026
Minor

AGN-151586 Injections · Moderate to Severe Forehead Lines (FHL) in Adult Participants

Enrollment closed, study ongoing

AbbViePhase 2 NCT07730554 Registry history of NCT07730554 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026
Minor

Adverse Events of Oral ABBV-932 · Depressive Episodes Associated With Bipolar I or II Disorder

Enrollment closed, study ongoing

Also in this update: Final enrollment: 84 participants (planned 200)

AbbViePhase 2 NCT07220460 Registry history of NCT07220460 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026
Minor

Itraconazole on ABBV-722 in Healthy Adult Participants

Trial completed

AbbViePhase 1 NCT07599761 Registry history of NCT07599761 on ClinicalTrials.gov (opens the registry)

Sep 30, 2026
Minor

Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

Trial completed

AbbViePhase 1 NCT07604558 Registry history of NCT07604558 on ClinicalTrials.gov (opens the registry)

Sep 30, 2026
Minor

TATOO · Treat-to-Target and Disease Modification · Crohn's Disease and Ulcerative Colitis in Real World Setting

Trial completed

Also in this update: Final enrollment: 1638 participants (planned 2000)

AbbVieNot specified NCT07421258 Registry history of NCT07421258 on ClinicalTrials.gov (opens the registry)

Oct 5, 2026
Minor

SURVIVE · Change in Disease State · Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece

Trial completed

Also in this update: Primary completion date changed from estimate of Dec 2026 to May 29, 2026

AbbVieNot specified NCT05317494 Registry history of NCT05317494 on ClinicalTrials.gov (opens the registry)

Oct 2, 2026
Minor

Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec · Neovascular Age-Related Macular Degeneration (nAMD)

Trial sites expanded: 133 → 136 locations

AbbViePhase 3 NCT07007065 Registry history of NCT07007065 on ClinicalTrials.gov (opens the registry)

Oct 20, 2026
Minor

AGN-151607-DP to Assess Adverse Events and Change in Disease Activity · Upper Limb Essential Tremor

Trial sites expanded: 3 → 20 locations

AbbViePhase 2 NCT07673107 Registry history of NCT07673107 on ClinicalTrials.gov (opens the registry)

Oct 22, 2026
Minor

MIGHTY · How Risankizumab Works in Young · Ulcerative Colitis

Trial sites expanded: 68 → 71 locations

And 1 more change in the last 30 days

AbbViePhase 3 NCT07071519 Registry history of NCT07071519 on ClinicalTrials.gov (opens the registry)

Oct 20, 2026
Minor

Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine · Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial sites expanded: 70 → 73 locations

AbbViePhase 2 NCT06890338 Registry history of NCT06890338 on ClinicalTrials.gov (opens the registry)

Oct 20, 2026
Minor

AndroMETa-CRC · Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab · Metastatic Colorectal Cancer

Trial sites expanded: 78 → 81 locations

And 1 more change in the last 30 days

AbbViePhase 2 NCT06820463 Registry history of NCT06820463 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

ABBV-295 · Obesity or Overweight With Weight-Related Comorbidities

Trial sites expanded: 57 → 61 locations

And 1 more change in the last 30 days

AbbViePhase 2 NCT07752979 Registry history of NCT07752979 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

AndroMETa-CRC · Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil · Refractory Metastatic Colorectal Cancer

Trial sites expanded: 84 → 87 locations

AbbViePhase 3 NCT07525206 Registry history of NCT07525206 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Advanced Therapies · Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Trial sites expanded: 61 → 64 locations

And 4 more changes in the last 30 days

AbbViePhase 2 NCT07697456 Registry history of NCT07697456 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

Up-AA · Upadacitinib Tablets in Adult and Adolescent · Severe Alopecia Areata

Trial sites reduced: 283 → 272 locations

AbbViePhase 3 NCT06012240 Registry history of NCT06012240 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

UP-RISING · Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Trial sites expanded: 72 → 75 locations

AbbVieNot specified NCT06712628 Registry history of NCT06712628 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

NAAVIGATE · Surabgene Lomparvovec Administered in the Suprachoroidal Space · Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

Trial sites expanded: 34 → 37 locations

AbbViePhase 2/3 NCT07592273 Registry history of NCT07592273 on ClinicalTrials.gov (opens the registry)

Oct 8, 2026
Minor

REVIVAL · Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine · Acute Myeloid Leukemia (AML)

Trial sites expanded: 32 → 35 locations

AbbViePhase 2/3 NCT07581002 Registry history of NCT07581002 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026
Minor

Change in Disease Activity and Adverse Events · Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Trial sites expanded: 16 → 21 locations

AbbViePhase 2 NCT07024784 Registry history of NCT07024784 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026
Minor

Treatment Patterns and Outcomes With Upadacitinib · Inflammatory Bowel Disease in Belgium

Trial sites expanded: 7 → 11 locations

AbbVieNot specified NCT06581042 Registry history of NCT06581042 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026
Minor

Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body · Non-Hodgkin's Lymphoma

Study completion pushed from Apr 2027 to Nov 2031

Also in this update: Primary completion moved earlier from Apr 2027 to Jan 2027

AbbViePhase 1 NCT06667687 Registry history of NCT06667687 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Minor

Target CD · Targeted Therapies · Moderate to Severe Crohn's Disease

Trial arms changed: 7 → 8

AbbViePhase 2 NCT06548542 Registry history of NCT06548542 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First posted	Trial	Phase	Status
2026-10-19	NCT07880756 Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin…	Phase 3	Recruiting
2026-10-13	NCT07871513 A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and…	Phase 2	Recruiting
2026-10-07	NCT07862764 A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients…		Not Yet Recruiting
2026-10-05	NCT07856706 A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults	Phase 1	Not Yet Recruiting
2026-09-28	NCT07843693 A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib…	Phase 1	Recruiting

Active trials by phase

Phase 1		51
Phase 1/2		10
Phase 2		49
Phase 2/3		10
Phase 3		61
Phase 4		4

Not charted: 50 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 51

Leukemia (21) · Lung Cancer (19) · Multiple Myeloma (17) · Non-Small Cell Lung Cancer (NSCLC) (16) · Crohn's Disease (15) · Ovarian Cancer (15) · Ulcerative Colitis (14) · Migraine (13) · Chronic Lymphocytic Leukemia (CLL) (11) · Acute Myeloid Leukemia (AML) (10)

Get alerts when AbbVie's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free